Meropenem Kabi

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, hospital‑acquired pneumonia, and meningitis in hospitalized adult and pediatric patients when alternative therapies are unsuitable.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections by inhibiting cell‑wall synthesis.

Complicated intra‑abdominal infections: provides broad‑spectrum coverage to achieve clinical cure and bacterial eradication. Complicated urinary tract infections: eliminates resistant uropathogens and resolves infection. Hospital‑acquired pneumonia: delivers rapid bactericidal activity against Gram‑negative and Gram‑positive organisms. Ventilator‑associated pneumonia: restores lung function by clearing pathogenic bacteria. Severe sepsis and septic shock: offers immediate antimicrobial control to support hemodynamic recovery. Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria.

Common Side Effects: - Nausea or vomiting - Diarrhea, which may be mild to moderate - Infusion‑site phlebitis or erythema - Elevated liver enzymes (ALT/AST) - Headache or dizziness - Rash or mild pruritus

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disease - Clostridioides difficile‑associated colitis - Anaphylactic or severe hypersensitivity reactions - Neutropenia or agranulocytosis - Acute renal failure or worsening renal function - Severe hepatic injury or jaundice

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal function: adjust dose in patients with impaired clearance and monitor serum creatinine. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactams. - Concomitant valproic acid: monitor for reduced seizure control and consider alternative therapy. - Superinfection: watch for overgrowth of non‑susceptible organisms, including fungi and C. difficile. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several drugs; clinicians should assess risk and monitor accordingly.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce plasma valproate levels, risking seizure breakthrough. - Other β‑lactam antibiotics: concurrent use increases risk of hypersensitivity reactions. - Probenecid: may raise meropenem plasma concentrations, potentially enhancing toxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides (e.g., gentamicin): additive nephrotoxicity; monitor renal function. - Loop diuretics (e.g., furosemide): may exacerbate renal impairment. - Warfarin: occasional alterations in INR; check coagulation parameters. - Non‑steroidal anti‑inflammatory drugs: increased risk of renal dysfunction. - Cytotoxic agents: heightened potential for renal toxicity; adjust dosing as needed.